SkinBioTherapeutics plc (SBTX) Ord GBP0.01

What is happening?

SkinBioTherapeutics have announced their intention to raise up to £4.7 million via a Placing for Institutional Investors and a Retail Offer for individual investors.

SkinBioTherapeutics have decided not to issue a prospectus as part of the fundraising. This means the Offer may only be open for a very short period, can close at any time without prior warning, and information can be limited to the Company announcement.

Key Details

• Applications are scheduled to close at 3:30pm on Thursday 19 June. However, due to the nature of the fundraising, applications can close at any time without prior warning.

• Shares are being offered at a fixed price of 17 pence.

• The minimum application for the Retail Offer is £100.

• The Retail Offer is capped at a maximum of £620,000, meaning that if the total value of applications received by the Issuer exceeds this figure, a scaling back policy is likely to be applied.

• Hargreaves Lansdown will receive 0.5% commission on the total allocation from the issuer as part of the Offer.

• By applying for shares in the Offer you are deemed to have read, understood and agreed to the HL Retail Offer Terms and Conditions, HL Retail Offer Risk Warning and the Company Announcement. These documents can be found in the Secure Messaging Centre of your online account.

What are my options?

Option 1 – Do nothing. If you don’t apply for shares by the deadline of 3:30pm on Thursday 19 June, the Offer will lapse.

Option 2 – You can purchase new shares at 17 pence.

If you wish to submit an order outside of the product you currently hold your shares in, please leave a note in the comments section.

To amend an application you’ve already submitted online, please enter a new instruction and this will overwrite any previous instruction you’ve given. You can cancel an instruction whilst applications are still open by submitting a new application and entering ‘0.00’.

Please note that any instruction you give must be based on the full details provided and not just on the summary of information provided above.

When do I have to decide by?

Any instruction to participate in the Retail Offer must be received by 3:30pm on Thursday 19 June. If no instruction is received the Offer will lapse.

Before submitting an instruction, you should carefully read the Company Announcement, HL Retail Offer Risk Warnings & Terms and Conditions which are attached to the Retail Offer notification. You can find this in the Secure Messaging Centre of your online account. By submitting an instruction, you are deemed to have read and understood these documents as well as agreed to any terms within.

What happens after I apply?

If you apply for shares, you’ll receive two further secure messages. The first will confirm your application and will be sent shortly after 4:30pm on Thursday 19 June. The second will confirm how many shares you’ve been allocated; this will be sent on Friday 20 June.

You’ll be able to view your application in the ‘Pending Orders’ tab of your online account from midday on Friday 20 June.

Once, your application has been accepted it’s not possible to cancel or amend your instruction. If you don’t have sufficient cash available to fund your allocation, we’ll sell a portion of your largest holding(s) to cover the cost.

Your shares are due to be credited shortly before 8am on Tuesday 24 June. However, this may be delayed in the event the company fails to deliver your shares to us by this time.

To assist the Company during the allocation process, we may be required to disclose the number of SkinBioTherapeutics shares you hold with Hargreaves Lansdown. We’ll do this by calculating the shares held in your Hargreaves Lansdown account at the close of business on Wednesday 18 June.

It should be noted that an application for the shares and any investment in the Company carry a number of risks. Investors should carry out their own investigations into the merits of an investment in the Company.

This message is not personal advice and is simply a summary of the SkinBioTherapeutics announcement.

If you require any assistance, please contact our Helpdesk on 0117 900 9000.